Dr Seila Selimovic is a Branch Chief / Program Director at the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the Department of Health and Human Services (HHS). Her branch supports the development of transformational platform technologies that enable improved access to medial countermeasures. Her portfolio ranges from microphysiological systems to digital medical countermeasures, in vitro diagnostics, and medical devices. Prior to BARDA, Seila was a Program Director at the National Institute of Biomedical Imaging and Bioengineering, and an AAAS Science and Technology Policy Fellow at the US Department of State. Seila completed her PhD in Condensed Matter Physics at Brandeis University and a postdoctoral fellowship at Harvard Medical School / Brigham & Women’s Hospital. Her academic research has centered on microfluidics, biosensors, tissue engineering, and microphysiological systems.
Stephanie Chan, PhD is a seasoned expert in the medical device and diagnostics sectors with over a decade of experience within startup ecosystems, venture capital, and product development. Having worked in cross-functional roles across biotechnology, she brings comprehensive expertise in research and development, clinical validation, manufacturing, quality assurance, and regulatory affairs—making her an invaluable resource for diagnostic development. With firsthand experience from the startup perspective, Stephanie offers innovative solutions and strategic recommendations to emerging companies in the biotech and diagnostics industries. Passionate about guiding startups through the complexities of commercialization, she is dedicated to advancing the next generation of diagnostic technologies.
Do you have a great company in the bioscience or medtech industry? Do you need wet-lab and/or fabrication space to develop and test your product?
